Mutua de Terrassa -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2020

  1. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

    Journal of Gastroenterology and Hepatology (Australia), Vol. 35, Núm. 12, pp. 2080-2087

2018

  1. Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial

    Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694

  2. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

  3. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 584-601

2016

  1. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project

    Inflammatory Bowel Diseases, Vol. 22, Núm. 3, pp. 583-589

2013

  1. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease

    Gastroenterology, Vol. 145, Núm. 4

  2. Safety of thiopurines and Anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease

    American Journal of Gastroenterology, Vol. 108, Núm. 3, pp. 433-440

  3. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

    Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760